This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 500mg | $230 | Check With Us |
| 1g | $400 | Check With Us |
| 5g | $1000 | Check With Us |
: Cat #: V2039 CAS #: 78110-38-0 Purity ≥ 98%
Description: Aztreonam (also known as SQ 26776) is a synthetic monocyclic beta-lactam antibiotic, used to treat Gram-negative aerobic bacteria infection. It has a very high affinity for penicillin-binding protein 3 (PBP-3). Aztreonam causes significant suppression of human colony forming unit-erythroid (cfu-e), burst forming unit-erythroid (bfu-e) and colony forming unit-granulocyte macrophage (cfu-gm) at both peak and trough serum concentrations in human bone marrow cells. Aztreonam is hydrolyzed at measurable rates by class A beta-lactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substraterange.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 435.43 |
|---|---|
| Molecular Formula | C13H17N5O8S2 |
| CAS No. | 78110-38-0 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 87 mg/mL (199.8 mM)r |
| Water: 11 mg/mL (25.26 mM)r | |
| Ethanol: <1 mg/mL | |
| SMILES Code | CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N |
| Synonyms | SQ 26,776; SQ-26,776; SQ26,776; SQ 26776; SQ26776; SQ-26776; Azactam; Azthreonam; Aztreonam; Urobactam |
| Protocol | In Vitro | In vitro activity: Aztreonam causes significant suppression of human colony forming unit-erythroid (cfu-e), burst forming unit-erythroid (bfu-e) and colony forming unit-granulocyte macrophage (cfu-gm) at both peak and trough serum concentrations in human bone marrow cells. Aztreonam is hydrolyzed at measurable rates by class A beta-lactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substraterange. Aztreonam is extremely stable as to the typical class C cephalosporinase of Citrobacter freundii, and acts as a competitive and progressive inhibitor for the beta-lactamase. Aztreonam (AZT) combined with clindamycin (CLDM) has synergistic effects on Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Haemophilus influenzae, which are sensitive or quasi-sensitive to CLDM, in the presence of CLDM at MIC or sub-MIC. Aztreonam reduces the cfu of some strains by 1 log unit without preserving the integrity of cystic fibrosis airway cell monolayers, while decreasing the biofilms of other clinical isolates by 4 log units and protecting the monolayers from being compromised. |
|---|---|---|
| In Vivo | Aztreonam (300 mg/kg) results in a significant decrease in the content of hepatic microsomal P450, while no significant change is observed in hepatic cytochrome b5 content and NADPH-cytochrome c (P450) reductase activity. | |
| Dosages | 300 mg/kg |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.2966 mL | 11.4829 mL | 22.9658 mL | 45.9316 mL |
| 5mM | 0.4593 mL | 2.2966 mL | 4.5932 mL | 9.1863 mL |
| 10mM | 0.2297 mL | 1.1483 mL | 2.2966 mL | 4.5932 mL |
| 20mM | 0.1148 mL | 0.5741 mL | 1.1483 mL | 2.2966 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.